title: Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
abstract: Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating beta-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of beta-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, beta-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of beta-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. Beta-catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.
authors.affiliation: INSERM U674 IFR105, Paris Saint-Louis, CEPH, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Zucman-Rossi
authors.forename: S
authors.initials: S
authors.lastname: Benhamouche
authors.forename: C
authors.initials: C
authors.lastname: Godard
authors.forename: S
authors.initials: S
authors.lastname: Boyault
authors.forename: G
authors.initials: G
authors.lastname: Grimber
authors.forename: C
authors.initials: C
authors.lastname: Balabaud
authors.forename: A S
authors.initials: AS
authors.lastname: Cunha
authors.forename: P
authors.initials: P
authors.lastname: Bioulac-Sage
authors.forename: C
authors.initials: C
authors.lastname: Perret
mesh_terms: D060466:Axin Protein; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D009154:Mutation / Q000235:genetics*; D012097:Repressor Proteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D014407:Tumor Cells, Cultured; D051176:beta Catenin / Q000235:genetics* / Q000378:metabolism
chemical_list: C555451:AXIN1 protein, human; D060466:Axin Protein; D012097:Repressor Proteins; D051176:beta Catenin